Cargando…
Andexanet Alfa: First Global Approval
Intravenous andexanet alfa [coagulation factor Xa (recombinant), inactivated-zhzo; Andexxa(®)] is a first-in-class recombinant modified factor Xa protein that has been developed by Portola Pharmaceuticals as a universal antidote to reverse anticoagulant effects of direct or indirect factor Xa inhibi...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061403/ https://www.ncbi.nlm.nih.gov/pubmed/29926311 http://dx.doi.org/10.1007/s40265-018-0940-4 |